According to final Overall Survival (OS) results from the Phase 3 FLAURA2 Trial, first-line Osimertinib plus chemotherapy significantly improved OS in comparison with Osimertinib monotherapy for patients with EGFR-mutated non-small cell lung…
Tag: Lung Cancer News
FDA Grants Breakthrough Therapy to Olomorasib to Treat Lung Cancer
Eli Lilly and Company has announced that US Food and Drug Administration (FDA) has granted breakthrough therapy designation to olomorasib, in combination with anti-PD1 therapy Keytruda for first-line treatment of patients with…
MSU Researchers Discovered Honeybees can Detect Lung Cancer
Lung Cancer is one of the leading causes of cancer-related deaths worldwide and early detection remains crucial for improving the survival rates. The researchers at Michigan State University (MSU) have found that…
Study Sheds Light on Rare Form of Lung Cancer
A rare and aggressive type of lung cancer called large cell neuroendocrine carcinoma (LCNEC) has a high chance of metastasis. It has no standard treatment and thus, suffer a poor survival rate….
FDA Approves Hernexeos for HER2-Mutant Advanced Lung Cancer
For the first time, FDA has given approval of an oral treatment of patients with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have human epidermal growth factor receptor 2…
World Lung Cancer Day: Combating the Problem of Late Detection
World Lung Cancer Day is observed on August 1 annually across the globe. It was first established in the year 2012 and is observed every year to raise awareness of lung cancer…
Lung Cancer Risk Factors in Adults with Interstitial Lung Disease
Interesting Lung Diseases (ILDs) are characterized by pathological changes in Pulmonary parenchyma. It is a group of conditions that cause inflammation in the lungs. This can be caused by medication, radiation therapy…
High-Dose Aumoltertinib for Untreated EGFR- Variant NSCLC
Aumoltertinib is a third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and has achieved potent efficacy for advanced EGFR-mutated non-small cell lung cancer patients. Phase 2 non-randomized clinical trial was conducted at…